Supplementary Appendix

Supplementary Methods

Data Sources

COVID-19 Testing Data

SARS-CoV-2 Testing PCR testing for SARS CoV-2 in England is undertaken by hospital and public health laboratories (Pillar 1), as well as by community testing (Pillar 2). Pillar 1 testing data is available from UKHSA labs and NHS hospitals for those with a clinical need, and health and care workers. Pillar 2 community testing is available to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste), anyone who is a contact of a confirmed case, care home staff and residents, and to those who have self-tested as positive using a lateral flow test (LFT).

Vaccination Data

The National Immunization Management System (NIMS) contains demographic information on the whole population of England who are registered with a general practice physician in England and is used to record all COVID-19 vaccinations. NIMS was accessed for dates of vaccination and manufacturer, sex, date of birth, ethnicity, and residential address. Addresses were used to determine index of multiple deprivation quintile and were also linked to Care Quality Commission registered care homes using the unique property reference number. Data on geography (NHS region), risk group status, clinically extremely vulnerable status, and health/social care worker were also extracted from the NIMS. Clinical risk groups included a range of chronic conditions as described in the Green Book (1), whereas the clinically extremely vulnerable group included persons who were considered to be at the highest risk for severe COVID-19, including those with immunosuppressed conditions and those with severe respiratory disease. Booster doses were identified as a third dose given at least 84 days after a second dose and administered after 13 September 2021. Individuals with four or more doses of vaccine, heterologous primary schedule or fewer than 19 days between their first and second dose were excluded.

Emergency Care Hospital Admission Data

Admissions due to an injury were excluded. Admissions were identified where the Emergency Care Destination code was either discharge to a ward, intensive care unit, coronary care unit, high dependency unit or where there was a date on which the decision to admit the patient was made. Admissions with an acute respiratory illness (ARI) SNOMED coded as the reason for attending emergency care were flagged.

Secondary Care Hospital Admission Data

SUS is the national electronic database of hospital admissions that provides timely updates of ICD-10 codes for completed hospital stays for all NHS hospitals in England. Up to 24 ICD-10 diagnoses fields can be completed in SUS for each admission with the first diagnosis field indicating the primary reason for admission. Length of stay was calculated as date of discharge – date of admission. Where multiple admissions linked to the same sample date the first admission after the sample date was retained and episode length calculated by summing the stay length for each admission. Data were

restricted to those with ARI in the first diagnosis field and where the length of stay was at least two days.

Control selection

For analyses involving hospitalised controls any negative tests that led to a hospitalisation within 21 days of a previous hospital negative test were excluded. A maximum of one negative test per person within each of the following approximate 3-month periods was selected at random: 26 April to 1 August 2021, 2 August 2021 to 21 November 2021, 22 November 2021 to 2 February 2022. For analyses involving all Pillar 2 symptomatic controls the same was done within this control group.

Supplementary Tables

Supplementary Table 1. SUS Acute respiratory illness ICD10 code list.

SUS A	cute respiratory illness ICD10 code list
J04*	Acute laryngitis and tracheitis
J09*	Influenza due to identified avian influenza virus
J10*	Influenza with pneumonia, other influenza virus identified
J11*	Influenza with pneumonia, virus not identified
J12*	Viral pneumonia, not elsewhere classified
J13*	Pneumonia due to Streptococcus pneumoniae
J14*	Pneumonia due to Haemophilus influenzae
J15*	Bacterial pneumonia, not elsewhere classified
J16*	Pneumonia due to other infectious organisms, not elsewhere classified
J17*	Pneumonia in diseases classified elsewhere
J18*	Pneumonia, organism unspecified
J20*	Acute bronchitis
J21*	Acute bronchiolitis
J22*	Unspecified acute lower respiratory infection
180*	ARDS (related to respiratory infection)
U07*	COVID-19, virus identified and not identified
U04*	Severe acute respiratory syndrome (SARS)

						Delta						Omicro	n		
				Cont	rols	Cases	All	Cases	s Hosp	Conti	rols	Cases	s All	Case	es Hosp
	Dose	Booster manufacturer	Interval (days)	n	%	n	%	n	%	n	%	n	%	n	%
				469,976		172,223		1,352		457,377		434,514		509	
sus	Unvaccinated			49,918	10.6%	48,699	28.3%	366	27.1%	29,062	6.4%	53,626	12.3%	93	18.3%
Vaccination Status	Dose 2*		175+	142,454	30.3%	92,917	54.0%	809	59.8%	89,641	19.6%	92,283	21.2%	84	16.5%
lation	Booster	Any	0-6	51,109	10.9%	21,257	12.3%	96	7.1%	40,877	8.9%	29,617	6.8%	5	1.0%
accir	Booster	BNT162b2	7+	225,962	48.1%	9,303	5.4%	76	5.6%	297,056	64.9%	258,297	59.4%	320	62.9%
>	Booster	ChAdOx1-S	7+	533	0.1%	47	0.0%	5	0.4%	741	0.2%	691	0.2%	7	1.4%
er	Female			284,136	60.5%	91,669	53.2%	624	46.2%	274,565	60.0%	230,789	53.1%	250	49.1%
Gender	Male			185,025	39.4%	80,291	46.6%	728	53.8%	182,025	39.8%	203,031	46.7%	258	50.7%
0	Missing			815	0.2%	263	0.2%	0	0.0%	787	0.2%	694	0.2%	1	0.2%
	40-44			80,921	17.2%	35,639	20.7%	0	0.0%	83,475	18.3%	94,518	21.8%	0	0.0%
	45-49			74,782	15.9%	30,300	17.6%	0	0.0%	78,924	17.3%	86,768	20.0%	0	0.0%
	50-54			89,098	19.0%	32,587	18.9%	0	0.0%	90,779	19.8%	87,744	20.2%	0	0.0%
	55-59			76,254	16.2%	25,591	14.9%	0	0.0%	75,520	16.5%	67,858	15.6%	0	0.0%
	60-64			55,023	11.7%	18,038	10.5%	0	0.0%	52,087	11.4%	41,777	9.6%	0	0.0%
Age	65-69			40,628	8.6%	12,894	7.5%	405	30.0%	34,908	7.6%	24,659	5.7%	116	22.8%
	70-74			30,900	6.6%	10,104	5.9%	405	30.0%	24,787	5.4%	18,125	4.2%	134	26.3%
	75-79			14,709	3.1%	4,876	2.8%	275	20.3%	11,152	2.4%	8,756	2.0%	103	20.2%
	80-84			4,094	0.9%	1,269	0.7%	144	10.7%	3,064	0.7%	2,332	0.5%	64	12.6%
	85-89			1,999	0.4%	580	0.3%	81	6.0%	1,518	0.3%	1,107	0.3%	49	9.6%
	90+			1,568	0.3%	345	0.2%	42	3.1%	1,163	0.3%	870	0.2%	43	8.4%
ity	African			3,922	0.8%	1,291	0.7%	14	1.0%	3,701	0.8%	5,492	1.3%	5	1.0%
Ethnicity	Any other Asian	background		5,405	1.2%	1,668	1.0%	14	1.0%	5,437	1.2%	6,253	1.4%	6	1.2%
Ξ	Any other Black	background		1,810	0.4%	787	0.5%	4	0.3%	1,590	0.3%	2,617	0.6%	0	0.0%

Supplementary Table 2. Descriptive characteristics of those included in the VE analysis for protection against symptomatic disease (cases all) and hospitalisation as assessed using the ECDS data following infection with either Delta or Omicron variants.

	Any other White background	30,310	6.4%	16,093	9.3%	89	6.6%	29,473	6.4%	39,506	9.1%	29	5.7%
	Any other ethnic group	6,239	1.3%	2,579	1.5%	12	0.9%	6,242	1.4%	7,630	1.8%	10	2.0%
	Any other mixed background	1,945	0.4%	774	0.4%	7	0.5%	1,894	0.4%	2,038	0.5%	2	0.4%
	Bangladeshi or British Bangladeshi	1,743	0.4%	678	0.4%	9	0.7%	1,741	0.4%	2,198	0.5%	4	0.8%
	British, Mixed British	355,004	75.5%	123,459	71.7%	1,036	76.6%	345,349	75.5%	302,173	69.5%	383	75.2%
	Caribbean	2,847	0.6%	1,443	0.8%	16	1.2%	2,474	0.5%	4,463	1.0%	9	1.8%
	Chinese	1,451	0.3%	490	0.3%	7	0.5%	1,503	0.3%	1,453	0.3%	3	0.6%
	Indian or British Indian	12,668	2.7%	3,191	1.9%	29	2.1%	12,322	2.7%	11,073	2.5%	7	1.4%
	Irish	3,313	0.7%	921	0.5%	7	0.5%	3,170	0.7%	2,649	0.6%	10	2.0%
	Pakistani or British Pakistani	5,791	1.2%	2,145	1.2%	19	1.4%	5,770	1.3%	7,135	1.6%	10	2.0%
	White and Asian	832	0.2%	301	0.2%	0	0.0%	865	0.2%	834	0.2%	0	0.0%
	White and Black African	656	0.1%	255	0.1%	0	0.0%	655	0.1%	850	0.2%	1	0.2%
	White and Black Caribbean	915	0.2%	404	0.2%	4	0.3%	840	0.2%	1,284	0.3%	2	0.4%
	Missing	35,125	7.5%	15,744	9.1%	85	6.3%	34,351	7.5%	36,866	8.5%	28	5.5%
	East of England	55,371	11.8%	19,965	11.6%	127	9.4%	54,106	11.8%	44,943	10.3%	46	9.0%
	London	56,857	12.1%	18,455	10.7%	121	8.9%	55,327	12.1%	61,545	14.2%	59	11.6%
ç	Midlands	89,571	19.1%	33,599	19.5%	274	20.3%	87,072	19.0%	82,976	173 $69.5%$ 383 75 463 $1.0%$ 9 1 453 $0.3%$ 3 0 073 $2.5%$ 7 1 649 $0.6%$ 10 2 135 $1.6%$ 10 2 135 $1.6%$ 10 2 834 $0.2%$ 0 0 850 $0.2%$ 1 0 284 $0.3%$ 2 0 866 $8.5%$ 28 5 943 $10.3%$ 46 9 976 $19.1%$ 100 19 399 $16.0%$ 98 19 3142 $16.2%$ 69 13 393 $7.7%$ 36 7 0 $0.0%$ 0 0 654 $19.5%$ 109 21 654 $19.7%$ 102 20 030 $20.7%$ 101 19	19.6%	
NHS Region	North East	70,243	14.9%	27,797	16.1%	287	21.2%	66,238	14.5%	69,399	16.0%	98	19.3%
IHS F	North West	65,199	13.9%	23,730	13.8%	180	13.3%	60,400	13.2%	71,916	16.6%	101	19.8%
2	South East	82,624	17.6%	28,623	16.6%	210	15.5%	85,855	18.8%	70,342	16.2%	69	13.6%
	South West	50,110	10.7%	20,054	11.6%	153	11.3%	48,378	10.6%	33,393	7.7%	36	7.1%
	Missing	. 1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
	1	72,363	15.4%	28,710	16.7%	284	21.0%	68,334	14.9%	81,965	18.9%	117	23.0%
es	2	84,074	17.9%	32,208	18.7%	275	20.3%	80,641	17.6%	84,654	19.5%	109	21.4%
IMD Quintiles	3	96,109	20.4%	35,481	20.6%	279	20.6%	93,614	20.5%	85,615	19.7%	102	20.0%
ID Q(4	104,605	22.3%	37,662	21.9%	278	20.6%	102,289	22.4%	90,030	20.7%	101	19.8%
≧	5	111,956	23.8%	37,790	21.9%	232	15.5%	111,706	24.4%	91,371	21.0%	80	13.6%
	Missing	869	0.2%	372	0.2%	4	0.3%	793	0.2%	879	0.2%	0	0.0%

Previously	No	410,326	87.3%	169,930	98.7%	1,347	99.6%	391,382	85.6%	395,115	90.9%	490	96.3%
positive	Yes	59,650	12.7%	2,293	1.3%	5	0.4%	65,995	14.4%	39,399	9.1%	19	3.7%
	Healthcare worker	18,031	3.8%	4,068	2.4%	4	0.3%	14,693	3.2%	11,743	2.7%	1	0.2%
Vaccine	CEV	44,973	9.6%	13,147	7.6%	475	35.1%	38,131	8.3%	32,486	7.5%	280	55.0%
priority groups	At risk**	119,372	25.4%	40,186	23.3%	14	1.0%	111,789	24.4%	95,944	22.1%	3	0.6%
	Severely immunosuppressed	5,571	1.2%	1,871	1.1%	116	8.6%	4,994	1.1%	5,734	1.3%	83	16.3%

* ChAdOx1-S primary course

**At risk is only those under 65

Supplementary Table 3. Effectiveness of the ChAdOx1-S and BNT162b2 booster vaccines against hospitalisation as defined by linkage to the accident and emergency (ECDS) data following infection with Delta or Omicron variants in adults aged 65 years and older in England.

Dose	Booster Manufacturer	Interval (days)	Controls	Cases	OR*	VE (95% CI)
					Delta	
Unvaccinated			2,685	366	Baseline	Baseline
Dose 2**		175+	21180	809	0.17 (0.15-0.2)	82.8 (79.9 to 85.3)
Booster	Any***	0-6	5,502	96	0.09 (0.07-0.12)	91.0 (88.5 to 93.0)
	BNT162b2	7+	64380	76	0.01 (0.01-0.02)	98.8 (98.4 to 99.1)
	ChAdOx1-S	7+	151	5	0.35 (0.13-0.91)	65.3 (8.7 to 86.8)
					Omicron	
Unvaccinated			1,561	93	Baseline	Baseline
Dose 2**		175+	4329	84	0.45 (0.32-0.63)	55.4 (37.2 to 68.4)
Booster	Any***	0-6	1,567	5	0.15 (0.06-0.38)	85.2 (61.7 to 94.3)
	BNT162b2	7+	63803	320	0.08 (0.06-0.1)	92.3 (89.8 to 94.2)
	ChAdOx1-S	7+	173	7	0.34 (0.15-0.8)	65.9 (19.9 to 85.4)

*Odds ratio

**ChAdOx1-S primary course

***ChAdOx1-S or BNT162b2

Supplementary Table 4. Descriptive characteristics of those included in the VE analysis for protection against hospitalisation as assessed using the SUS data following infection with either Delta or Omicron variants.

						Delta	a					Omic	ron		
				Ove	erall	Contr		Ca	ases	Ove	erall		trols	Ca	ises
	Dose	Booster manufacturer	Interval (days)	n	%	n	%	n	%	n	%	n	%	n	%
				23,227	100.0%	17,377	74.8%	5,850	25.2%	11,052	100.0%	9,021	81.6%	2,031	18.4%
tus	Unvaccinate	ed		3,327	14.3%	1,327	7.6%	2,000	34.2%	1,120	10.1%	517	5.7%	603	29.7%
ו Sta	Dose 2*		175+	10,248	44.1%	7,000	40.3%	3,248	55.52%	2,026	18.3%	1,596	17.7%	430	21.2%
atior	Booster	Any	0-6	1,366	5.9%	1,123	6.5%	243	4.15%	388	3.5%	361	4.0%	27	1.3%
Vaccination Status	Booster	BNT162b2	7+	8,239	35.5%	7,884	45.4%	355	6.07%	7,448	67.4%	6,495	72.0%	953	46.9%
>	Booster	ChAdOx1-S	7+	47	0.2%	43	0.2%	4	0.07%	70	0.6%	52	0.6%	18	0.9%
Pillar	Pillar 1			20,960	90.2%	16,976	97.7%	3,984	68.1%	10,374	93.9%	8,810	97.7%	1,564	77.0%
Pil	Pillar 2			2,267	9.8%	401	2.3%	1,866	31.9%	678	6.1%	211	2.3%	467	23.0%
5	Female			12,333	53.1%	9,594	55.2%	2,739	46.8%	5,955	53.9%	4,940	54.8%	1,015	50.0%
Gender	Male			10,806	46.5%	7,699	44.3%	3,107	53.1%	5,041	45.6%	4,028	44.7%	1,013	49.9%
	Missing			88	0.4%	84	0.5%	4	0.1%	56	0.5%	53	0.6%	3	0.1%
	65-69			3,147	13.5%	1,896	10.9%	1,251	21.4%	1,389	12.6%	1,096	12.1%	293	14.4%
	70-74			4,590	19.8%	3,106	17.9%	1,484	25.4%	2,120	19.2%	1,683	18.7%	437	21.5%
Age	75-79			4,696	20.2%	3,446	19.8%	1,250	21.4%	2,223	20.1%	1,815	20.1%	408	20.1%
Ą	80-84			3,514	15.1%	2,691	15.5%	823	14.1%	1,709	15.5%	1,363	15.1%	346	17.0%
	85-89			3,526	15.2%	2,924	16.8%	602	10.3%	1,731	15.7%	1,440	16.0%	291	14.3%
	90+			3,754	16.2%	3,314	19.1%	440	7.5%	1,880	17.0%	1,624	18.0%	256	12.6%
	African			127	0.5%	62	0.4%	65	1.1%	55	0.5%	23	0.3%	32	1.6%
	Any other A	sian background		154	0.7%	89	0.5%	65	1.1%	71	0.6%	47	0.5%	24	1.2%
icity	Any other B	lack background		65	0.3%	34	0.2%	31	0.5%	35	0.3%	20	0.2%	15	0.7%
Ethnicity	Any other V	Vhite background		1,084	4.7%	746	4.3%	338	5.8%	490	4.4%	371	4.1%	119	5.9%
	Any other e	- thnic group		199	0.9%	125	0.7%	74	1.3%	83	0.8%	58	0.6%	25	1.2%
	•	nixed background		54	0.2%	40	0.2%	14	0.2%	31	0.3%	21	0.2%	10	0.5%

	Bangladeshi or British Bangladeshi	61	0.3%	37	0.2%	24	0.4%	28	0.3%	18	0.2%	10	0.5%
	British, Mixed British	19,165	82.5%	14,768	85.0%	4,397	75.2%	9,137	82.7%	7,647	84.8%	1,490	73.4%
	Caribbean	240	1.0%	94	0.5%	146	2.5%	133	1.2%	54	0.6%	79	3.9%
	Chinese	40	0.2%	15	0.1%	25	0.4%	13	0.1%	6	0.1%	7	0.3%
	Indian or British Indian	323	1.4%	209	1.2%	114	1.9%	160	1.4%	109	1.2%	51	2.5%
	Irish	231	1.0%	185	1.1%	46	0.8%	123	1.1%	99	1.1%	24	1.2%
	Pakistani or British Pakistani	291	1.3%	169	1.0%	122	2.1%	148	1.3%	96	1.1%	52	2.6%
	White and Asian	14	0.1%	9	0.1%	5	0.1%	4	0.0%	3	0.0%	1	0.0%
	White and Black African	10	0.0%	6	0.0%	4	0.1%	5	0.0%	5	0.1%	0	0.0%
	White and Black Caribbean	39	0.2%	21	0.1%	18	0.3%	18	0.2%	9	0.1%	9	0.4%
	Missing	1,130	4.9%	768	4.4%	362	6.2%	518	4.7%	435	4.8%	83	4.1%
	East of England	2,549	11.0%	1,997	11.5%	552	9.4%	1,133	10.3%	972	10.8%	161	7.9%
	London	2,390	10.3%	1,704	9.8%	686	11.7%	1,152	10.4%	798	8.8%	354	17.4%
u	Midlands	4,749	20.4%	3,554	20.5%	1,195	20.4%	2,451	22.2%	2,012	22.3%	439	21.6%
Regic	North East	4,433	19.1%	3,172	18.3%	1,261	21.6%	2,039	18.4%	1,662	18.4%	377	18.6%
NHS Region	North West	3,376	14.5%	2,546	14.7%	830	14.2%	1,678	15.2%	1,312	14.5%	366	18.0%
	South East	3,412	14.7%	2,697	15.5%	715	12.2%	1,621	14.7%	1,406	15.6%	215	10.6%
	South West	2,318	10.0%	1,707	9.8%	611	10.4%	978	8.8%	859	9.5%	119	5.9%
	1	5,443	23.4%	3,913	22.5%	1,530	26.2%	2,727	24.7%	2,095	23.2%	632	31.1%
es	2	4,862	20.9%	3,590	20.7%	1,272	21.7%	2,293	20.7%	1,833	20.3%	460	22.6%
uintil	3	4,575	19.7%	3,441	19.8%	1,134	19.4%	2,118	19.2%	1,739	19.3%	379	18.7%
IMD Quintiles	4	4,583	19.7%	3,532	20.3%	1,051	18.0%	2,167	19.6%	1,841	20.4%	326	16.1%
2	5	3,718	16.0%	2,873	16.5%	845	14.4%	1,723	15.6%	1,496	16.6%	227	11.2%
	Missing	46	0.2%	28	0.2%	18	0.3%	24	0.2%	17	0.2%	7	0.3%
Previously	No	20,958	90.2%	15,158	87.2%	5,800	99.1%	9,717	87.9%	7,786	86.3%	1,931	95.1%
positive	Yes	2,269	9.8%	2,219	12.8%	50	0.9%	1,335	12.1%	1,235	13.7%	100	4.9%
Vaccine priority	Healthcare worker	16	0.1%	12	0.1%	4	0.1%	6	0.1%	5	0.1%	1	0.0%
groups	CEV	12,340	53.1%	9,915	57.1%	2,425	41.5%	6,188	56.0%	5,046	55.9%	1,142	56.2%

At risk*	115	0.5%	69	0.4%	46	0.8%	55	0.5%	47	0.5%	8	0.4%
Severely immunosuppressed	1,967	8.5%	1,510	8.7%	457	7.8%	1,022	9.2%	795	8.8%	227	11.2%

* ChAdOx1-S primary course

**At risk is only those und

References

1. UK Health Security Agency. COVID-19: the green book, chapter 14a. Immunisation against infectious diseases: UK Health Security Agency,; 2020.